Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

29.98
-1.2700-4.06%
Post-market: 29.980.00000.00%18:40 EDT
Volume:745.54K
Turnover:22.78M
Market Cap:3.45B
PE:-17.42
High:31.26
Open:30.96
Low:29.92
Close:31.25
52wk High:42.00
52wk Low:14.06
Shares:114.98M
Float Shares:64.72M
Volume Ratio:1.04
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7211
EPS(LYR):-1.7211
ROE:-28.29%
ROA:-17.27%
PB:5.04
PE(LYR):-17.42

Loading ...

Stock Track | NewAmsterdam Pharma (NAMS) Soars 5% as Analysts Maintain Buy Ratings with High Price Targets

Stock Track
·
Nov 10, 2025

RBC Capital Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Nov 10, 2025

NewAmsterdam Pharma Grants Inducement Share Options to New Hire

Reuters
·
Nov 08, 2025

RBC Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Nov 07, 2025

RBC Raises Price Target on NewAmsterdam Pharma to $44 From $39, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Nov 06, 2025

NewAmsterdam Pharma Company Nv : Needham Raises Target Price to $46 From $40

THOMSON REUTERS
·
Nov 06, 2025

NewAmsterdam Pharma Is Maintained at Buy by Needham

Dow Jones
·
Nov 06, 2025

NewAmsterdam Pharma Company Nv : Piper Sandler Raises Target Price to $60 From $37

THOMSON REUTERS
·
Nov 05, 2025

NewAmsterdam Pharma Company NV reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 05, 2025

NewAmsterdam Pharma reports Q3 revenue of $0.3 million and cash position of $756 million

Reuters
·
Nov 05, 2025

Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Dow Jones
·
Nov 05, 2025

NewAmsterdam Pharma Unveils Phase 3 Obicetrapib Data at AHA 2025 Sessions

Reuters
·
Oct 30, 2025

NewAmsterdam Pharma’s REMBRANDT Trial: A Potential Game-Changer in Cardiovascular Treatment

TIPRANKS
·
Oct 28, 2025

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women

GlobeNewswire
·
Oct 23, 2025

NewAmsterdam Pharma Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Oct 20, 2025

NewAmsterdam Pharma assumed with a Buy at H.C. Wainwright

TIPRANKS
·
Oct 20, 2025

NewAmsterdam Pharma Company (NAMS) Gets a Hold from Goldman Sachs

TIPRANKS
·
Oct 18, 2025

NewAmsterdam Pharma Is Maintained at Buy by Citigroup

Dow Jones
·
Oct 17, 2025

Could Caristo Collaboration Reveal NewAmsterdam Pharma’s (NAMS) Real Edge in Cardiovascular Innovation?

Simply Wall St.
·
Oct 17, 2025

NewAmsterdam Pharma price target raised to $50 from $42 at Citi

TIPRANKS
·
Oct 17, 2025